1 completed, 1 not yet recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
Follow Solifenacin 5 mg: new trials by email Literature Review of Solifenacin 5 mg trials Research Report on Solifenacin 5 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial Mirabegron 25mg, Solifenacin 5 mg, Tolterodine 4 mg - Urinary Bladder, Overactive | Phase 3 | Not yet recruiting | Far Eastern Memorial Hospital | 220 | 2025-08-07 | 2025-08-11 |
| A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg - Urinary Bladder Diseases, Urinary Bladder Overactive | Phase 3 | Completed | Astellas Pharma Europe Ltd. | 2174 | 2013-07-10 | 2024-10-31 |
Urinary Bladder, Overactive (2) · Nocturia (1) · Urinary Bladder Diseases (1) · Urinary Incontinence (1) · Urologic Diseases (1)
Astellas Pharma Europe Ltd. (1) · Far Eastern Memorial Hospital (1)
Armenia (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Ireland (1) · Israel (1)